Drug Trial Radar · NCT05588843
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
187
Actual
Start
Nov 25, 2022
Primary completion
Feb 10, 2026
Study completion Dec 2, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of SAR443122 compared to placebo in participants with moderate to severe UC. Dose selection for further clinical development will be based on the multiple efficacy, safety and PK parameters. The study consists of 4 parallel arms (3 dose groups of SAR443122 vs placebo) to assess the efficacy and safety of SAR443122 in participants with moderate to severe UC. All participants will receive a total of 52 weeks (a 12-week induction treatment phase and a 40-week maintenance phase) of study treatment, except if treatment should be discontinued per investigator's assessment. At the end of the first 12 weeks of induction treatment, all participants in clinical response or remission will be offered study treatment up to 40 weeks and will continue with the same blinded treatment that was assigned. Participants who do not achieve clinical response or remission at the end of the initial 12 weeks induction treatment will roll over in an open-label treatment arm and will be treated with SAR443122 at the highest tested dose. In addition, participants from the maintenance treatment that lose clinical efficacy at any time up to V10/Week 40 (Week 28 of maintenance) will be offered to roll over in the open-label treatment arm with SAR443122 at the highest dose.
Conditions
- Colitis Ulcerative
Interventions
SAR443122Drug
oral capsule
PlaceboDrug
oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who achieve clinical remission at Week 12 by modified Mayo Score (mMS)Time frame: At Week 12
Locations
106 sites in 19 countries. Site status is shown where the registry gives one.
Om Research - Lancaster - 15th Street West- Site Number : 8400014
Lancaster, California
Agile Clinical Research Trials- Site Number : 8400024
Atlanta, Georgia
Endeavor Health - Evanston Hospital- Site Number : 8400027
Evanston, Illinois
BVL Research- Site Number : 8400015
Liberty, Missouri
Vector Clinical Trials- Site Number : 8400004
Las Vegas, Nevada
Sanmora Bespoke Clinical Research Solutions- Site Number : 8400016
East Orange, New Jersey
NY Scientific- Site Number : 8400013
Brooklyn, New York
Pioneer Clinical Research - New York- Site Number : 8400017
New York, New York
Gastro One - Walnut Run Road- Site Number : 8400002
Cordova, Tennessee
Houston Methodist Hospital- Site Number : 8400023
Houston, Texas
1960 Family Practice- Site Number : 8400019
Houston, Texas
GI Alliance - Mansfield- Site Number : 8400010
Mansfield, Texas
Integrity Research - Sugar Land- Site Number : 8400026
Sugar Land, Texas
Richmond VA Medical Center- Site Number : 8400022
Richmond, Virginia
Investigational Site Number : 0320002
Buenos Aires, Argentina
Investigational Site Number : 0320004
Córdoba, Argentina
Investigational Site Number : 0320005
Córdoba, Argentina
Investigational Site Number : 0320007
Salta, Argentina
Investigational Site Number : 0320006
CABA, Buenos Aires, Argentina
Investigational Site Number : 0320003
Rosario, Santa Fe Province, Argentina
Investigational Site Number : 0320001
San Miguel de Tucumán, Tucumán Province, Argentina
Investigational Site Number : 1520004
Talcahuano, Biobio, Chile
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520005
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520006
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520007
Viña del Mar, Valparaiso, Chile
Investigational Site Number : 1560001
Guangzhou, China
Investigational Site Number : 1560004
Hangzhou, China
Investigational Site Number : 1560003
Hefei, China
Investigational Site Number : 1560006
Nanchang, China
Investigational Site Number : 1560007
Nanjing, China
Investigational Site Number : 1560005
Shanghai, China
Investigational Site Number : 1560002
Shenyang, China
Investigational Site Number : 2030007
České Budějovice, Czechia
Investigational Site Number : 2030001
Hradec Králové, Czechia
Investigational Site Number : 2030002
Klatovy, Czechia
Investigational Site Number : 2030003
Prague, Czechia
Investigational Site Number : 2500007
Marseille, France
Investigational Site Number : 2500008
Nantes, France
Investigational Site Number : 2500006
Neuilly-sur-Seine, France
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.